Pfizer Inc. (NYSE:PFE) Holdings Trimmed by Iron Gate Global Advisors LLC

Iron Gate Global Advisors LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 10,777 shares of the biopharmaceutical company’s stock after selling 1,991 shares during the quarter. Iron Gate Global Advisors LLC’s holdings in Pfizer were worth $312,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Olistico Wealth LLC bought a new position in Pfizer in the 2nd quarter valued at about $25,000. Apella Capital LLC boosted its position in shares of Pfizer by 19.4% in the second quarter. Apella Capital LLC now owns 17,611 shares of the biopharmaceutical company’s stock valued at $488,000 after acquiring an additional 2,858 shares during the period. CVA Family Office LLC raised its stake in shares of Pfizer by 119.9% during the second quarter. CVA Family Office LLC now owns 11,998 shares of the biopharmaceutical company’s stock worth $336,000 after acquiring an additional 6,542 shares in the last quarter. Fiduciary Alliance LLC purchased a new position in shares of Pfizer in the second quarter worth $204,000. Finally, Triangle Securities Wealth Management boosted its holdings in shares of Pfizer by 12.7% during the 2nd quarter. Triangle Securities Wealth Management now owns 14,274 shares of the biopharmaceutical company’s stock valued at $399,000 after buying an additional 1,610 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock opened at $25.82 on Tuesday. The company has a market cap of $146.32 billion, a P/E ratio of 34.89, a price-to-earnings-growth ratio of 0.71 and a beta of 0.65. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business has a fifty day moving average of $27.83 and a two-hundred day moving average of $28.49.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.17) earnings per share. As a group, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Stockholders of record on Friday, November 8th were issued a dividend of $0.42 per share. The ex-dividend date was Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.51%. Pfizer’s payout ratio is presently 227.03%.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on PFE shares. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Sanford C. Bernstein began coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, Citigroup assumed coverage on Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $32.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.